These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

286 related items for PubMed ID: 14673879

  • 1. Chronic treatment with small doses of cabergoline prevents dopa-induced dyskinesias in parkinsonian monkeys.
    Bélanger N, Grégoire L, Hadj Tahar A, Bédard PJ.
    Mov Disord; 2003 Dec; 18(12):1436-41. PubMed ID: 14673879
    [Abstract] [Full Text] [Related]

  • 2. Sustained cabergoline treatment reverses levodopa-induced dyskinesias in parkinsonian monkeys.
    Hadj Tahar A, Grégoire L, Bangassoro E, Bédard PJ.
    Clin Neuropharmacol; 2000 Dec; 23(4):195-202. PubMed ID: 11020123
    [Abstract] [Full Text] [Related]

  • 3. Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of L-Dopa in parkinsonian monkeys.
    Grégoire L, Samadi P, Graham J, Bédard PJ, Bartoszyk GD, Di Paolo T.
    Parkinsonism Relat Disord; 2009 Jul; 15(6):445-52. PubMed ID: 19196540
    [Abstract] [Full Text] [Related]

  • 4. Brain 5-HT(2A) receptors in MPTP monkeys and levodopa-induced dyskinesias.
    Riahi G, Morissette M, Parent M, Di Paolo T.
    Eur J Neurosci; 2011 May; 33(10):1823-31. PubMed ID: 21501255
    [Abstract] [Full Text] [Related]

  • 5. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
    Muñoz A, Li Q, Gardoni F, Marcello E, Qin C, Carlsson T, Kirik D, Di Luca M, Björklund A, Bezard E, Carta M.
    Brain; 2008 Dec; 131(Pt 12):3380-94. PubMed ID: 18952677
    [Abstract] [Full Text] [Related]

  • 6. Striatal Akt/GSK3 signaling pathway in the development of L-Dopa-induced dyskinesias in MPTP monkeys.
    Morissette M, Samadi P, Hadj Tahar A, Bélanger N, Di Paolo T.
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Apr 16; 34(3):446-54. PubMed ID: 20026151
    [Abstract] [Full Text] [Related]

  • 7. Changes of AMPA receptors in MPTP monkeys with levodopa-induced dyskinesias.
    Ouattara B, Hoyer D, Grégoire L, Morissette M, Gasparini F, Gomez-Mancilla B, Di Paolo T.
    Neuroscience; 2010 Jun 02; 167(4):1160-7. PubMed ID: 20303391
    [Abstract] [Full Text] [Related]

  • 8. The acute antiparkinsonian and antidyskinetic effect of AFQ056, a novel metabotropic glutamate receptor type 5 antagonist, in L-Dopa-treated parkinsonian monkeys.
    Grégoire L, Morin N, Ouattara B, Gasparini F, Bilbe G, Johns D, Vranesic I, Sahasranaman S, Gomez-Mancilla B, Di Paolo T.
    Parkinsonism Relat Disord; 2011 May 02; 17(4):270-6. PubMed ID: 21315648
    [Abstract] [Full Text] [Related]

  • 9. Implication of NMDA receptors in the antidyskinetic activity of cabergoline, CI-1041, and Ro 61-8048 in MPTP monkeys with levodopa-induced dyskinesias.
    Ouattara B, Belkhir S, Morissette M, Dridi M, Samadi P, Grégoire L, Meltzer LT, Di Paolo T.
    J Mol Neurosci; 2009 Jun 02; 38(2):128-42. PubMed ID: 18704766
    [Abstract] [Full Text] [Related]

  • 10. Prolonged kynurenine 3-hydroxylase inhibition reduces development of levodopa-induced dyskinesias in parkinsonian monkeys.
    Grégoire L, Rassoulpour A, Guidetti P, Samadi P, Bédard PJ, Izzo E, Schwarcz R, Di Paolo T.
    Behav Brain Res; 2008 Jan 25; 186(2):161-7. PubMed ID: 17868931
    [Abstract] [Full Text] [Related]

  • 11. Changes in glutamate receptors in dyskinetic parkinsonian monkeys after unilateral subthalamotomy.
    Jourdain VA, Morin N, Grégoire L, Morissette M, Di Paolo T.
    J Neurosurg; 2015 Dec 25; 123(6):1383-93. PubMed ID: 25932606
    [Abstract] [Full Text] [Related]

  • 12. Effect of non-dopaminergic drug treatment on Levodopa induced dyskinesias in MPTP monkeys: common implication of striatal neuropeptides.
    Tamim MK, Samadi P, Morissette M, Grégoire L, Ouattara B, Lévesque D, Rouillard C, Di Paolo T.
    Neuropharmacology; 2010 Jan 25; 58(1):286-96. PubMed ID: 19576910
    [Abstract] [Full Text] [Related]

  • 13. Conversion from dopamine agonists to cabergoline: an open-label trial in 128 patients with advanced Parkinson disease.
    Linazasoro G, Spanish Dopamine Agonists Study Group.
    Clin Neuropharmacol; 2008 Jan 25; 31(1):19-24. PubMed ID: 18303487
    [Abstract] [Full Text] [Related]

  • 14. Reduction of L-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease.
    Johnston TH, Fox SH, McIldowie MJ, Piggott MJ, Brotchie JM.
    J Pharmacol Exp Ther; 2010 Jun 25; 333(3):865-73. PubMed ID: 20231306
    [Abstract] [Full Text] [Related]

  • 15. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
    Bracco F, Battaglia A, Chouza C, Dupont E, Gershanik O, Marti Masso JF, Montastruc JL, PKDS009 Study Group.
    CNS Drugs; 2004 Jun 25; 18(11):733-46. PubMed ID: 15330687
    [Abstract] [Full Text] [Related]

  • 16. [Development of dyskinesias induced by treatment for Parkinson's disease: potential role of first exposure to L-DOPA (or phenomenon of priming)].
    Damier P, Tremblay L, Féger J, Hirsch EC.
    Rev Neurol (Paris); 2000 Mar 25; 156(3):224-35. PubMed ID: 10740093
    [Abstract] [Full Text] [Related]

  • 17. Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-naive primates.
    Smith LA, Jackson MJ, Al-Barghouthy G, Rose S, Kuoppamaki M, Olanow W, Jenner P.
    Mov Disord; 2005 Mar 25; 20(3):306-14. PubMed ID: 15490461
    [Abstract] [Full Text] [Related]

  • 18. AQW051, a novel and selective nicotinic acetylcholine receptor α7 partial agonist, reduces l-Dopa-induced dyskinesias and extends the duration of l-Dopa effects in parkinsonian monkeys.
    Di Paolo T, Grégoire L, Feuerbach D, Elbast W, Weiss M, Gomez-Mancilla B.
    Parkinsonism Relat Disord; 2014 Nov 25; 20(11):1119-23. PubMed ID: 25172125
    [Abstract] [Full Text] [Related]

  • 19. Repeated administration of piribedil induces less dyskinesia than L-dopa in MPTP-treated common marmosets: a behavioural and biochemical investigation.
    Smith LA, Tel BC, Jackson MJ, Hansard MJ, Braceras R, Bonhomme C, Chezaubernard C, Del Signore S, Rose S, Jenner P.
    Mov Disord; 2002 Sep 25; 17(5):887-901. PubMed ID: 12360537
    [Abstract] [Full Text] [Related]

  • 20. Treatment of Parkinson's disease and restless legs syndrome with cabergoline, a long-acting dopamine agonist.
    Porter MC, Appiah-Kubf LS, Chaudhuri KR.
    Int J Clin Pract; 2002 Sep 25; 56(6):468-74. PubMed ID: 12166546
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.